San Diego, California, January 27, 2016: Stemedica announced completion of enrollment into “A Phase I/IIa, Multi-Center, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic…
Planned to Launch in the Fourth Quarter 2015 in the United States as the First Alzheimer’s Clinical Trial Using Intravenous Administration of Ischemia-Tolerant Mesenchymal Stem Cells (itMSCs) SAN DIEGO and Epalinges, Switzerland — June 9, 2015 — Stemedica ….
Stemedica a leader in adult allogeneic stem cell manufacturing, research and development, announced today the completion of enrollment and treatment of patients in a Phase I study with Stemedica’s lead product Stemedyne-MSC. These specially…
